CCCC
C4 Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Buy"
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CCCC
C4 Therapeutics, Inc.
A developer of novel therapies for cancer and other diseases using its proprietary Cell Selection and Engineering (CSE) platform
Biological Technology
10/07/2015
10/02/2020
NASDAQ Stock Exchange
110
12-31
Common stock
490 Arsenal Way, Suite 200, Watertown, MA 02472
--
C4 Therapeutics, Inc., was incorporated in Delaware on October 7, 2015. The company is a biopharmaceutical company dedicated to harnessing the body's natural regulation of protein levels to develop new therapeutic drug candidates to target and destroy disease-causing proteins to treat cancer, neurodegenerative diseases and other diseases.
Company Financials
EPS
CCCC has released its 2025 Q3 earnings. EPS was reported at -0.44, versus the expected -0.38, missing expectations. The chart below visualizes how CCCC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CCCC has released its 2025 Q3 earnings report, with revenue of 11.23M, reflecting a YoY change of -26.90%, and net profit of -32.17M, showing a YoY change of -30.41%. The Sankey diagram below clearly presents CCCC's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
